ClinicalTrials.gg
CompletedNCT04522739STANDUpdated Nov 20, 2026Results posted

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

A Phase 4 interventional study of Spironolactone and Placebo in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Emory University · Phase 4, Interventional, and Prevention

How we know

Updated Nov 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Cognitive Dysfunction by Emory University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Emory University.

Enrollment
17th of 19
27 · median 45
Started
2022
the only one that year
Phase 4
3 of 24
none open now
Registered
15th of 24
by date

Among the 24 studies in Cognitive Dysfunction by Emory University, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 4, and was the 15th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

6 of the 24 studies in Cognitive Dysfunction by Emory University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cognitive Dysfunction by Emory University, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.

Read the detailed description

In 2018, 5.5 million older adults in the United States were diagnosed with Alzheimer's disease, and it is predicted that 15 million people will be diagnosed with dementia, including Alzheimer's disease by 2060. Older African Americans adults are more likely to be diagnosed with Alzheimer's disease as compared to Whites. Research search studies on high blood pressure show that African Americans have higher levels of the hormone aldosterone that can be involved with regulation of blood pressure and blood vessels. Research studies also show that changes in blood vessels in the brain from higher aldosterone levels are related to changes in thinking skills and memory (cognition). Spironolactone is a drug that blocks aldosterone and has been used to treat high blood pressure for 60 years. More recently, this drug has shown to have the potential to decrease declines in thinking skills and memory.

Spironolactone is widely used in clinical practice and is well-tolerated by younger and older persons. As such, this study is designed to learn how a small group of older African American adults with mild cognitive impairment will tolerate the drug. Persons who are eligible for the study and agree to participate will receive spironolactone or a placebo and be monitored for drug side effects for one year.

During the study, the researchers will monitor changes in thinking and memory and blood vessel stiffness, in addition to side effects that may be related to the drug. Study tests include questionnaires that evaluate thinking skills and memory, and an ultrasound that measures the stiffness of blood vessels in the neck which deliver blood to the brain. The thinking and memory tests and ultrasound will be performed at the beginning of the study, then repeated at the end of the study.

The results of this study can justify a larger size study of spironolactone in older African Americans with mild cognitive impairment. The study has the potential to identify a new use for a well-known drug that is safe and widely used in current clinical practice. Further, the results from this study can address a racial difference in Alzheimer's disease and preserve the health of the brain as people age.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated form
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Self-identified African American
  • Blood pressure (BP) and hypertension criteria: normotensive and hypertensive participants will be eligible

    • Normotensive criteria: BP 110-140/40-90 mmHg and not receiving any treatment for hypertension
    • Hypertensive criteria: only controlled hypertensives will be eligible with BP range as in the normotensive criteria of 110-140/40-90 mmHg
  • MCI defined as:

    • Abnormal memory function per the Logical Memory subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised (the maximum score is 25):

      • Score \<11 for 16 or more years of education
      • Score \<9 for 8-15 years of education
      • Score \<6 for \<7 years of education
      • (MoCA) score 13-25
      • Preserved general functional performance per Functional Assessment Questionnaire (FAQ)\<9

Exclusion criteria

Exclusion Criteria:

  • History of stroke in the previous three years
  • \<13 or the inability to follow instructions to perform cognitive testing
  • Inability to participate in the study procedures: cognitive tests (communication limitations from language or other factors)
  • Active medical problem/symptom that interferes with the study procedures, e.g., chest pain, shortness of breath, or abdominal pain
  • Deemed ineligible by study investigators due to safety issues or non-compliance
  • History of the inability to tolerate treatment with an aldosterone antagonist
  • Hypertension

    • Uncontrolled defined as a BP > 140/90 mmHg
    • Current therapy with RAAS modulating medications, i.e., angiotensin II receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEi), renin inhibitor, or aldosterone antagonist such as eplerenone (Inspra) due to the risk of hyperkalemia and the interference with the renin angiotensin aldosterone system (RAAS) system
  • Renal disease (baseline creatinine > 2.0 mg/dL)
  • Hyperkalemia (K+ > 5.5 milliequivalent (mEq)/dL)
  • Other neurological or psychiatric conditions that could impact cognition, e.g., Parkinson's disease and related movement disorders, multiple sclerosis, epilepsy, or schizophrenia, untreated major depressive disorder, and other psychotic disorders
  • Abnormal thyroid stimulating hormone (TSH) (>10 milliunits (mU)/L) or vitamin B12 (\<250 pg/mL) as they can impact cognitive function. If the potential participant's TSH and/or vitamin B12 levels are abnormal, then the PI may enroll that person if it is thought the lab abnormalities are unrelated and do not affect cognitive function
  • Active medical or psychiatric disease, which in the judgment of the study investigators affects participant safety or the scientific integrity of the study
  • Uncontrolled congestive heart failure reflected by poor exercise tolerance and shortness of breath
  • Women of , i.e., non-menopausal
  • When potential participants are not capable of providing due to their cognitive impairment and a study partner/legally authorized representative (LAR) is not available to sign consent forms on their behalf
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Spironolactone

    Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.

    Drug: Spironolactone

  • Placebo comparator
    Placebo

    Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.

    Drug: Placebo

Interventions

  • Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.

    Also known as: Aldactone

  • DrugPlacebo

    A placebo to match spironolactone will be taken orally once per day for 12 months.

06

What researchers measure

Primary outcomes

  1. Count of Adverse Events

    The safely of the study treatment is assessed with the total number of adverse events experienced in each study arm.

    Time frame: Month 12

  2. Number of Participants Not Completing The Study

    The tolerability of the study treatment is assessed by participant attrition in each study arm. The number of participants who left the study prior to completing the 12 month study.

    Time frame: Month 12

Secondary outcomes

  1. Change From Baseline in Trail Making Test Part A Score

    In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.

    Time frame: Baseline, Month 12

  2. Change From Baseline in Trail Making Test Part B Score

    Part B of the Trail Making Test (TMT) includes a sheet of paper with circles with numbers (1-13) and letters (A-L). Participants are asked to draw lines connecting the circles in ascending order of the numbers and letters, alternating between numbers and letters. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 75 seconds. Times greater than 273 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.

    Time frame: Baseline, Month 12

  3. Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score

    The RAVLT test is a 15-item neuropsychological measure of attention, concentration, verbal learning, and memory. Total scores range from 0 to 15, where higher scores indicate better recall. The change from baseline is a negative number when the Month 12 score is higher than the baseline score, indicating better recall at the follow-up time point.

    Time frame: Baseline, Month 12

  4. Change From Baseline in Number Span Forward Test Score

    The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers forwards. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.

    Time frame: Baseline, Month 12

  5. Change From Baseline in Number Span Backward Test Score

    The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers backward. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.

    Time frame: Baseline, Month 12

07

Results

Posted Nov 20, 2026

Participant flow

Participant enrollment began September 6, 2022 and follow-up assessments for the Month 12 time point were completed by September 23, 2025.

Participant flow — Overall Study
MilestoneSpironolactonePlacebo
Started1314
Completed1114
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryCount of Adverse Events

The safely of the study treatment is assessed with the total number of adverse events experienced in each study arm.

Time frame:
Month 12
Reported as:
Number · adverse events
Count of Adverse Events
adverse eventsSpironolactonePlacebo
Count of Adverse Events2427
PrimaryNumber of Participants Not Completing The Study

The tolerability of the study treatment is assessed by participant attrition in each study arm. The number of participants who left the study prior to completing the 12 month study.

Time frame:
Month 12
Reported as:
Count of participants · Participants
Number of Participants Not Completing The Study
ParticipantsSpironolactonePlacebo
Number of Participants Not Completing The Study20
SecondaryChange From Baseline in Trail Making Test Part A Score

In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.

Time frame:
Baseline, Month 12
Reported as:
Mean · seconds
Change From Baseline in Trail Making Test Part A Score
secondsSpironolactonePlacebo
Change From Baseline in Trail Making Test Part A Score-17.2 ± 18.50.36 ± 43.2
SecondaryChange From Baseline in Trail Making Test Part B Score

Part B of the Trail Making Test (TMT) includes a sheet of paper with circles with numbers (1-13) and letters (A-L). Participants are asked to draw lines connecting the circles in ascending order of the numbers and letters, alternating between numbers and letters. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 75 seconds. Times greater than 273 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.

Time frame:
Baseline, Month 12
Reported as:
Mean · seconds
Change From Baseline in Trail Making Test Part B Score
secondsSpironolactonePlacebo
Change From Baseline in Trail Making Test Part B Score-17.9 ± 65.9-13.7 ± 100.0
SecondaryChange in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score

The RAVLT test is a 15-item neuropsychological measure of attention, concentration, verbal learning, and memory. Total scores range from 0 to 15, where higher scores indicate better recall. The change from baseline is a negative number when the Month 12 score is higher than the baseline score, indicating better recall at the follow-up time point.

Time frame:
Baseline, Month 12
Reported as:
Mean · score on a scale
Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score
score on a scaleSpironolactonePlacebo
Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score-2.31 ± 4.070.71 ± 4.81
SecondaryChange From Baseline in Number Span Forward Test Score

The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers forwards. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.

Time frame:
Baseline, Month 12
Reported as:
Mean · digits repeated correctly
Change From Baseline in Number Span Forward Test Score
digits repeated correctlySpironolactonePlacebo
Change From Baseline in Number Span Forward Test Score-1.08 ± 3.33-0.50 ± 4.62
SecondaryChange From Baseline in Number Span Backward Test Score

The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers backward. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.

Time frame:
Baseline, Month 12
Reported as:
Mean · digits repeated correctly
Change From Baseline in Number Span Backward Test Score
digits repeated correctlySpironolactonePlacebo
Change From Baseline in Number Span Backward Test Score-1.00 ± 3.11-0.43 ± 2.47

Adverse events

Collected over Information on adverse events was collected from the time participants initiated the study treatment and continued through the final assessment (up to 12 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Spironolactone0/13 (0%)0/13 (0%)13/13 (100%)
Placebo0/14 (0%)1/14 (7.1%)14/14 (100%)
Most frequent serious events
Most frequent serious events
EventSpironolactonePlacebo
Asthma exacerbationRespiratory, thoracic and mediastinal disorders0/131/14
Most frequent other events
Showing 10 of 28
Most frequent other events
EventSpironolactonePlacebo
DizzinessGeneral disorders3/131/14
FatigueGeneral disorders3/132/14
LightheadednessGeneral disorders3/132/14
WeaknessGeneral disorders0/133/14
Allergic reaction of unknown causeImmune system disorders2/130/14
Low blood pressureVascular disorders2/131/14
ConstipationGastrointestinal disorders0/132/14
Muscle crampsMusculoskeletal and connective tissue disorders0/132/14
Absence seizureNervous system disorders1/130/14
Coronavirus 2019 (COVID-19) infectionInfections and infestations1/131/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)SpironolactonePlaceboTotal
Mean69.2 ± 4.7172.2 ± 7.6571.0 ± 6.54
Sex: Female, Male
Sex: Female, Male(Participants)SpironolactonePlaceboTotal
Female41216
Male9211
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)SpironolactonePlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)SpironolactonePlaceboTotal
United States131427
08

Study locations

1 site
  • Emory Clinic at Executive Park
    Atlanta, Georgia 30329, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, will be shared.

Supporting information: Study protocol

Time frame: The data will become available beginning 36 months and ending three years following article publication.

Access criteria: The data will be shared with researchers who provide a methodically sound proposal in order to achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months, the data will be available in Emory University's data warehouse but without investigator support other than deposited metadata. Proposals should be directed to antoine.trammell@emory.edu. The requestors will need to sign a data access agreement to gain access to the data.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Sep 2025, 36 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion. A results delay was requested in Sep 2026.

Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's 36 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 21, 2020
StartActual
Sep 6, 2022
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Results delay requested
Sep 21, 2026
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Enrollment
25→27
Nov 20, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore Attrition rateNow Number of Participants Not Completing The StudyTime frame: Year 1 → Month 12
  • Time frameCount of Adverse EventsYear 1 → Month 12
  • DescriptionCount of Adverse Events: how it is measured was reworded
Nov 20, 2026
Documents
Secondary outcomes
3 edited, 2 added, 3 removed
What changed in the outcomes
  • EditedChange From Baseline in Trail Making Test Part A ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
  • EditedChange From Baseline in Trail Making Test Part B ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
  • EditedChange From Baseline in DigitNumber Span Forward Test ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
  • AddedChange in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall ScoreTime frame: Baseline, Month 12
  • AddedChange From Baseline in Number Span Backward Test ScoreTime frame: Baseline, Month 12
  • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall ScoreTime frame: Baseline, Month 6, Month 12
  • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall ScoreTime frame: Baseline, Month 6, Month 12
  • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index ScoreTime frame: Baseline, Month 6, Month 12
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Results posted
    Enrollment 25→27
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Attrition rateNow Number of Participants Not Completing The StudyTime frame: Year 1 → Month 12
    • Time frameCount of Adverse EventsYear 1 → Month 12
    • DescriptionCount of Adverse Events: how it is measured was reworded
    Secondary outcomes 3 edited, 2 added, 3 removed
    What changed in the outcomes
    • EditedChange From Baseline in Trail Making Test Part A ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
    • EditedChange From Baseline in Trail Making Test Part B ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
    • EditedChange From Baseline in DigitNumber Span Forward Test ScoreTime frame: Baseline, Month 6, Month 12 → Baseline, Month 12
    • AddedChange in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall ScoreTime frame: Baseline, Month 12
    • AddedChange From Baseline in Number Span Backward Test ScoreTime frame: Baseline, Month 12
    • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall ScoreTime frame: Baseline, Month 6, Month 12
    • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall ScoreTime frame: Baseline, Month 6, Month 12
    • RemovedChange in Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index ScoreTime frame: Baseline, Month 6, Month 12
    + 1 other change: index terms
  2. Oct 30, 2026
    Minor edits only
    + 3 other changes: verification date, registry dates and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04522739
Lead sponsor
Emory University
Collaborators
Alzheimer's Association
Responsible party
Antoine Trammell (Associate Professor, Emory University) — Principal investigator
First posted
Aug 21, 2020
Start date
Sep 6, 2022
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Antoine Trammell, MD, MPH
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spironolactone

Start the discussion